News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
712,872 Results
Type
Article (42238)
Company Profile (436)
Press Release (670198)
Multimedia
Podcasts (75)
Webinars (13)
Section
Business (208703)
Career Advice (2021)
Deals (36002)
Drug Delivery (104)
Drug Development (83561)
Employer Resources (173)
FDA (16418)
Job Trends (15089)
News (352725)
Policy (33063)
Tag
2024 BioCapital Digital (10)
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (10)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (8)
2024 Pharm Country Digital (7)
2024 Pharm Country Standard (5)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (8)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (2)
Academia (2642)
Accelerated approval (6)
Adcomms (24)
Allergies (84)
Alliances (50917)
ALS (91)
Alzheimer's disease (1418)
Antibody-drug conjugate (ADC) (126)
Approvals (16404)
Artificial intelligence (253)
Autoimmune disease (22)
Automation (15)
Bankruptcy (371)
Best Places to Work (11841)
BIOSECURE Act (18)
Biosimilars (103)
Biotechnology (330)
Bladder cancer (65)
Brain cancer (26)
Breast cancer (266)
Cancer (2124)
Cardiovascular disease (177)
Career advice (1687)
Career pathing (29)
CAR-T (150)
Cell therapy (423)
Cervical cancer (19)
Clinical research (67612)
Collaboration (826)
Compensation (506)
Complete response letters (24)
COVID-19 (2641)
CRISPR (42)
C-suite (233)
Cystic fibrosis (105)
Data (2067)
Decentralized trials (2)
Denatured (27)
Depression (47)
Diabetes (260)
Diagnostics (6407)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (123)
Drug pricing (104)
Drug shortages (26)
Duchenne muscular dystrophy (95)
Earnings (87532)
Editorial (37)
Employer branding (21)
Employer resources (147)
Events (115378)
Executive appointments (692)
FDA (17595)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (742)
Gene editing (108)
Generative AI (20)
Gene therapy (309)
GLP-1 (733)
Government (4486)
Grass and pollen (4)
Guidances (50)
Healthcare (19143)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (120)
Indications (27)
Infectious disease (2782)
Inflammatory bowel disease (139)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (91)
Interviews (311)
IPO (16775)
IRA (43)
Job creations (3699)
Job search strategy (1434)
Kidney cancer (9)
Labor market (35)
Layoffs (488)
Leadership (17)
Legal (7982)
Liver cancer (73)
Lung cancer (306)
Lymphoma (141)
Machine learning (5)
Management (58)
Manufacturing (284)
MASH (65)
Medical device (13488)
Medtech (13493)
Mergers & acquisitions (19728)
Metabolic disorders (686)
Multiple sclerosis (75)
NASH (19)
Neurodegenerative disease (96)
Neuropsychiatric disorders (30)
Neuroscience (1956)
NextGen: Class of 2025 (6755)
Non-profit (4546)
Northern California (2540)
Now hiring (37)
Obesity (372)
Opinion (222)
Ovarian cancer (75)
Pain (84)
Pancreatic cancer (80)
Parkinson's disease (151)
Partnered (21)
Patents (220)
Patient recruitment (100)
Peanut (47)
People (58556)
Pharmaceutical (86)
Pharmacy benefit managers (19)
Phase I (21241)
Phase II (29831)
Phase III (22068)
Pipeline (1126)
Policy (132)
Postmarket research (2601)
Preclinical (9061)
Press Release (67)
Prostate cancer (100)
Psychedelics (37)
Radiopharmaceuticals (261)
Rare diseases (393)
Real estate (6014)
Recruiting (66)
Regulatory (22655)
Reports (46)
Research institute (2415)
Resumes & cover letters (351)
Rett syndrome (4)
RNA editing (4)
RSV (40)
Schizophrenia (73)
Series A (133)
Series B (86)
Service/supplier (11)
Sickle cell disease (57)
Southern California (2205)
Special edition (17)
Spinal muscular atrophy (152)
Sponsored (29)
Startups (3758)
State (2)
Stomach cancer (14)
Supply chain (63)
Tariffs (18)
The Weekly (46)
United States (22355)
Vaccines (681)
Venture capitalists (38)
Weight loss (248)
Women's health (36)
Worklife (16)
Date
Today (119)
Last 7 days (456)
Last 30 days (2491)
Last 365 days (34060)
2025 (9151)
2024 (36301)
2023 (41015)
2022 (52277)
2021 (56764)
2020 (54920)
2019 (47416)
2018 (35697)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (736)
Alabama (57)
Alaska (7)
Arizona (236)
Arkansas (14)
Asia (39156)
Australia (6522)
California (5842)
Canada (1934)
China (496)
Colorado (256)
Connecticut (275)
Delaware (135)
Europe (85537)
Florida (855)
Georgia (199)
Idaho (57)
Illinois (523)
India (24)
Indiana (300)
Iowa (10)
Japan (149)
Kansas (105)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (867)
Massachusetts (4463)
Michigan (216)
Minnesota (383)
Mississippi (2)
Missouri (79)
Montana (29)
Nebraska (25)
Nevada (58)
New Hampshire (66)
New Jersey (1669)
New Mexico (30)
New York (1655)
North Carolina (998)
North Dakota (7)
Northern California (2540)
Ohio (197)
Oklahoma (14)
Oregon (37)
Pennsylvania (1303)
Puerto Rico (11)
Rhode Island (30)
South America (1109)
South Carolina (19)
South Dakota (1)
Southern California (2205)
Tennessee (96)
Texas (868)
Utah (173)
Virginia (140)
Washington D.C. (61)
Washington State (547)
West Virginia (3)
Wisconsin (52)
712,872 Results for "denali therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
ALS
Denali Suffers Another ALS Fail With Phase II/III Flop
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and Amylyx have seen similarly disappointing results.
January 7, 2025
·
2 min read
·
Tristan Manalac
ALS
HEALEY ALS Trial Serves Up More Disappointment as Denali, AbbVie/Calico Fail
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the latest setbacks for the controversial platform trial, the results from which have largely mirrored the dismal success rate in ALS overall.
January 10, 2025
·
5 min read
·
Heather McKenzie
Neurodegenerative disease
Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier
After some high-profile crashes, the one-time biotech darling is inching toward success with its Hunter syndrome treatment, which today began a rolling BLA for accelerated approval.
April 2, 2025
·
5 min read
·
Dan Samorodnitsky
Press Releases
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
February 27, 2025
·
13 min read
Press Releases
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
April 2, 2025
·
8 min read
Press Releases
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
·
4 min read
Business
Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Denali Therapeutics Inc. reported financial results for the first quarter ended March 31, 2024, and provided business highlights.
May 7, 2024
·
13 min read
Press Releases
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 14, 2025
·
10 min read
Press Releases
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
February 6, 2025
·
9 min read
Press Releases
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
January 9, 2025
·
6 min read
1 of 71,288
Next
